Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in CashChange in ReceivablesChange in Working CapitalDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Addex Therapeutics (ADXN) Change in Account Payables (2022 - 2025)

Historic Change in Account Payables for Addex Therapeutics (ADXN) over the last 4 years, with Q2 2025 value amounting to -$185.3 billion.

  • Addex Therapeutics' Change in Account Payables rose 8200.68% to -$185.3 billion in Q2 2025 from the same period last year, while for Jun 2025 it was -$28.1 billion, marking a year-over-year decrease of 10418.06%. This contributed to the annual value of -$1.3 million for FY2024, which is 9080.47% down from last year.
  • Latest data reveals that Addex Therapeutics reported Change in Account Payables of -$185.3 billion as of Q2 2025, which was up 8200.68% from $170.6 billion recorded in Q1 2025.
  • In the past 5 years, Addex Therapeutics' Change in Account Payables ranged from a high of $1411.3 billion in Q4 2023 and a low of -$1224.9 billion during Q3 2024
  • Moreover, its 4-year median value for Change in Account Payables was -$154425.5 (2022), whereas its average is $1.0 billion.
  • In the last 5 years, Addex Therapeutics' Change in Account Payables tumbled by 24661080904.49% in 2023 and then soared by 1894637454055.39% in 2024.
  • Over the past 4 years, Addex Therapeutics' Change in Account Payables (Quarter) stood at -$821184.2 in 2022, then surged by 171865443.79% to $1411.3 billion in 2023, then dropped by 14.16% to $1211.5 billion in 2024, then tumbled by 115.29% to -$185.3 billion in 2025.
  • Its Change in Account Payables was -$185.3 billion in Q2 2025, compared to $170.6 billion in Q1 2025 and $1211.5 billion in Q4 2024.